Chronic exposure to cadmium compounds (Cd2+) is one of
the major public health problems facing humans in the 21st century.
Cd2+ in the human body accumulates primarily in the
kidneys which leads to renal dysfunction and other adverse health effects.
Efforts to find a safe and effective drug for removing Cd2+
from the kidneys have largely failed. We developed and synthesized a new
chemical, sodium (S)-2-(dithiocarboxylato((2S,3R,4R,5R)-2,3,4,5,6
pentahydroxyhexyl)amino)-4-(methylthio) butanoate (GMDTC). Here we report that
GMDTC has a very low toxicity with an acute lethal dose (LD50) of more than
10,000 mg/kg or 5000 mg/kg body weight, respectively, via oral
or intraperitoneal injection in mice and rats. In in vivo
settings, up to 94% of Cd2+ deposited in the kidneys
of Cd2+-laden rabbits was removed and excreted
via urine following a safe dose of GMDTC treatment for four
weeks, and renal Cd2+ level was reduced from 12.9
μg/g to 1.3 μg/g kidney weight. We observed similar results in
the mouse and rat studies. Further, we demonstrated both in in
vitro and in animal studies that the mechanism of transporting
GMDTC and GMDTC-Cd complex into and out of renal tubular cells is likely
assisted by two glucose transporters, sodium glucose cotransporter 2 (SGLT2) and
glucose transporter 2 (GLUT2). Collectively, our study reports that GMDTC is
safe and highly efficient in removing deposited Cd2+ from
kidneys assisted by renal glucose reabsorption system, suggesting that GMDTC may
be the long-pursued agent used for preventive and therapeutic purposes for both
acute and chronic Cd2+ exposure.